VolitionRX Ltd

VolitionRX’s epigenetic blood tests promise non‑invasive, early cancer detection and type differentiation, positioning the company as a potential leader in oncology diagnostics.

VolitionRX Ltd. is a Singapore-based company specializing in epigenetic cancer detection blood tests, which aim to identify unique nucleosome patterns in the blood to detect and differentiate various cancer types.

VolitionRx Ltd. reported a 441% increase in revenue for Q1 2025, driven by commercialization efforts for its Nu.Q platform, with analysts projecting continued growth and a potential revenue of $7.5 million for the fiscal year.